A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.

Phase 3

Completed

• Conditions: Pulmonary Hypertension
• Interventions: Drug: Riociguat (Adempas, BAY63-2521); Drug: Placebo

• Registration Number: NCT00855465
• Lead Sponsor: Bayer

Brief Summary

The aim of the study is to assess the efficacy and safety of different doses of BAY63-2521, given orally for 16 weeks, in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH).

Detailed Description

Adverse event data will be covered in Adverse events section.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2008-12-15
• Study Start: 2009-02-23
• Study First Submitted QC: 2009-03-03
• Study First Posted: 2009-03-04
• Primary Completion: 2012-06-27
• Study Completion: 2012-06-27
• Results First Submitted: 2013-11-04
• Results First Submitted QC: 2014-01-25
• Results First Posted: 2014-03-11
• Status Verified: 2023-11
• Last Update Submitted: 2023-11-03
• Last Update Posted: 2023-11-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 262

Inclusion Criteria

• Male and female patients with CTEPH either inoperable or with persistent or recurrent PH after surgery.

Read More

Exclusion Criteria

• All types of pulmonary hypertension except subtypes 4.1 and 4.2 of the Venice Clinical Classification of Pulmonary Hypertension.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Riociguat (Adempas, BAY63-2521)_individual dose titration	Riociguat (Adempas, BAY63-2521)	Participants received Riociguat orally as a film-coated tablet up to 2.5mg three times daily (tid) (titration between 1.0 mg and 2.5 mg tid based on an individual dose titration (IDT) scheme) for 16 weeks
Placebo	Placebo	Participants received Placebo orally as a film-coated tablet three times daily (tid) for 16 weeks

Primary Outcome Measures

Name	Time	Method
6 Minutes Walking Distance (6MWD) - Change From Baseline to Week 16	Baseline and week 16	6-minute walking distance (6MWD) is a measure for the objective evaluation of a participant's functional exercise capacity.

Secondary Outcome Measures

Name	Time	Method
Pulmonary Vascular Resistance (PVR) - Change From Baseline to Week 16	Baseline and week 16	The pulmonary vascular resistance (PVR) is a calculated hemodynamic parameter. PVR is derived from the directly measured parameters mean pulmonary arterial pressure (PAPmean) and pulmonary capillary wedge pressure (PCWP), divided by the cardiac output (CO). PVR and PAPmean are acquired during a right heart catheterization. CO is a calculated hemodynamic parameter, too. Formula: PVR = 80\*(PAPmean - PCWP)/CO
Percentage of Participants With Clinical Worsening	At week 16	The combined endpoint "time to clinical worsening", made up of the following components, defined by the first occurrence: all-cause mortality; heart/lung transplantation; rescue endarterectomy; first hospitalization due to pulmonary hypertension; start of a new pulmonary hypertension treatment; persistent worsening of 6MWD or WHO functional class due to deterioration of PH.
Living With Pulmonary Hypertension (LPH) Questionnaire - Change From Baseline to Week 16	Baseline and week 16	The self-reported Living with Pulmonary Hypertension (LPH) questionnaire is designed to measure the effects of PH and PH-specific treatments on an individual's quality of life. The LPH total score can range from 0 (best) to 105 (worst).
N-terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP) - Change From Baseline to Week 16	Baseline and week 16	N-terminal pro-brain natriuretic peptide (NT-proBNP) levels in the blood are used for screening, diagnosis of acute congestive heart failure (CHF) and may be useful to establish prognosis in heart failure.
World Health Organization (WHO) Functional Class - Change From Baseline to Week 16	Baseline and week 16	The WHO functional assessment of pulmonary arterial hypertension ranged from functional class I (Patients with PH but without resulting limitation of physical activity) to class IV (Patients with PH with inability to carry out any physical activity without symptoms. These patients manifest signs of right-heart failure.). Changes to a lower WHO functional class resemble improvement; changes to a higher functional class resemble deterioration of PAH.
Borg CR 10 Scale - Change From Baseline to Week 16	Baseline and week 16	The Borg CR10 Scale is a participant reported outcome measure used in clinical diagnosis of e.g. breathlessness and dyspnea. It documents the participant's exertion during a physical test. Low values indicate low levels of exertion; high values indicate more intense exertion reported by the participant. The score ranges from 0 ("Nothing at all") to 10 ("Extremely strong - Maximal").
EQ-5D Utility Score - Change From Baseline to Week 16	Baseline and week 16	EQ-5D utility score is a Quality-of-Life participant reported outcome measure. The utility score is calculated based on five questions concerning problems with mobility, self-care, usual activities, pain/discomfort and anxiety/depression. An increase in the utility score represents an improvement in quality of life. The score ranges from -0.594 (worst answer in all five questions) to 1 (best answer in all five questions).

Trial Locations

Locations (2)

Hopital Antoine Beclere; 🇫🇷 Clamart Cedex, France

Vseobecna fakultni nemocnice; 🇨🇿 Praha 2, Czechia